Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Target Recruit Count
- 54
- Registration Number
- NCT04730999
- Locations
- 🇮🇹
UOC Oncologia Medica 1 - AOU Careggi, Firenze, Italy
🇮🇹Istituto Oncologico Veneto IRCCS, Padova, Italy
🇮🇹Oncologia medica - Policlinico San Martino, Genova, Italy
Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 63
- Registration Number
- NCT04728230
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 101
- Registration Number
- NCT04712903
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 120
- Registration Number
- NCT04702880
- Locations
- 🇺🇸
Local Institution - 0060, Cincinnati, Ohio, United States
🇺🇸Local Institution - 0002, Durham, North Carolina, United States
🇦🇺Local Institution - 0004, Murdoch, Western Australia, Australia
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Muhammad Furqan
- Target Recruit Count
- 30
- Registration Number
- NCT04699838
- Locations
- 🇺🇸
University of Illinois Medical Center, Chicago, Illinois, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 100
- Registration Number
- NCT04696939
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 28
- Registration Number
- NCT04696575
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT04684017
- Locations
- 🇨🇳
Shanghai Chest hospital, Shanghai, Shanghai, China
Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 69
- Registration Number
- NCT04683198
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
- Conditions
- Interventions
- Procedure: Biospecimen CollectionDrug: CarboplatinDrug: EtoposideBiological: FilgrastimDrug: IfosfamideProcedure: Magnetic Resonance ImagingDrug: MesnaBiological: PegfilgrastimProcedure: Peripheral Blood Stem Cell TransplantationOther: Questionnaire AdministrationRadiation: Radiation TherapyProcedure: Second-Look SurgeryDrug: Thiotepa
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 160
- Registration Number
- NCT04684368
- Locations
- 🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire, United States
🇦🇺Sydney Children's Hospital, Randwick, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.